MB Therapeutics strengthens its growth strategy with the appointment of a Chief Business Officer
In the context of rapid growth and expansion into new markets, MB Therapeutics is strengthening its development by appointing a Chief Business Officer (CBO) to its executive team. This key role is designed to accelerate the company’s commercial expansion, both nationally and internationally, by reinforcing relationships with hospital partners, industry stakeholders, and healthtech startups.
An experienced leader to support this momentum
With 15 years of experience in the pharmaceutical industry, he has held executive positions within a CDMO (Contract Development and Manufacturing Organization), notably at Fareva, a company specialized in industrial subcontracting. His career has given him a hands-on understanding of production requirements, a strong quality culture, and in-depth insight into the commercial and partnership dynamics of the pharmaceutical sector.
He also brings solid expertise in developing strategic partnerships with pharmaceutical companies, healthcare institutions, and innovation stakeholders, with a long-term, collaborative approach.
Structuring geographic and strategic partnership development
As CBO, Matthieu plays a central role in the commercial expansion of MB Therapeutics. He leads the rollout of the MB model, contributes to sales growth, and supports the development of strategic partnerships both in France and internationally.
His arrival marks a new chapter in an already well-established momentum, at a pivotal moment in the company’s growth. This renewed dynamic within the leadership team reflects a clear ambition: to structure our commercial development, accelerate ongoing projects, and prepare for the next stages of our expansion—both nationally and abroad.
Conclusion
The creation of this new role marks a strategic milestone in the ongoing structuring of MB Therapeutics. It reflects our ambition to build a robust, open, and partnership-driven organization, while preserving the agility and spirit of innovation that define our identity. We wish Matthieu every success in his new role.
